Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Researchers at Mayo Clinic are exploring the use of a new drug called ataciguat to manage AVS. Results from preclinical and clinical studies, published in Circulation, show that ataciguat has the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

Researchers at Mayo Clinic are exploring the use of a new drug called ataciguat to manage AVS. In AVS, calcium deposits build up and narrow the aortic valve, forcing the heart to work harder to ...